The Board of Directors of Broncus Holding Corporation announced that it has resolved to change the chief executive officer of the Company (the Chief Executive Officer'') from Mr. Zhan to Mr. Hong Xu (Mr. Xu''), with effect from September 1, 2023, as Mr. Zhan would like to devote more time to his other commercial and personal affairs. Mr. Xu will be responsible for the Company's overall strategic planning and business direction. Mr. Hong XU (), aged 37, was appointed as an executive Director and the chief technology officer of Company (CTO'') on May 6, 2021.

He joined Group as the chief technology officer of Hangzhou Broncus Medical Co. Ltd., a subsidiary of the Company and hereinafter as ``Broncus Hangzhou'') in February 2018. As at the date of this announcement, Mr. Xu has applied for more than 600 patents as an inventor.

In June 2022, Mr. Xu obtained the qualification certificate issued by the Zhejiang Province Bureau of Human Resources and Social Security in the field of medical devices, and obtained the title of senior engineer''. Mr. Xu has over 12 years of industry experience. Prior to joining Group, Mr. Xu served as the associate general manager at Shenzhen Chuangling Image Technology Co.

Ltd., a subsidiary of APT Medical Inc., an electrophysiological and vascular interventional medical device company from September 2014 to February 2018 and held positions of manager of R&D, associate manager of R&D department and R&D engineer at APT Medical Inc. from July 2010 to March 2015. Mr. Xu obtained a bachelor's degree in polymer material and engineering from Sichuan University in Chengdu, China, in June 2010. Mr. Xu currently serves as a legal representative and manager in a number of major subsidiaries of Group, including Broncus Hangzhou, Broncus Medical (China) Co.

Ltd. and Hangzhou Kunpeng Medical Co. Ltd.